NEW YORK (GenomeWeb News) – Ross Perot has donated $20 million to the University of Texas MD Anderson Cancer Center to develop new cancer therapies, the center announced yesterday.
The funds will be divided equally between MD Anderson's Institute for Personalized Cancer Therapy and a Center for Targeted Therapy.
IPCT leverages discoveries made by its researchers to determine specific genetic and molecular abnormalities in a patient's cancer so that appropriate therapies can be prescribed. CTT is one of seven centers in the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer at MD Anderson and is focused on coordinating all stages of the new-drug discovery and development process in order to accelerate new and less toxic drugs to the clinic from the research lab.
According to John Mendelsohn, president of MD Anderson, the donation from Perot will accelerate research into genetic blueprints, the identification of biomarkers, the development of cancer drugs, and the testing of new drugs in clinical trials.
"These funds will enable our clinicians and researchers to advance the translation of science into new and improved cancer treatments," Mendelsohn said in a statement.
Perot, who ran for President in 1992 and 1996, is the founder of Electronic Data Systems and Perot Systems.